Beyond the Price Tag: What Generic Drug Tariffs Could Mean for Patients’ Access to Medication

Editor's Note: Patient Worthy is honored to share this article, originally written by Renzo Luzzatti, President and CEO of US-Rx Care. The White House recently announced intent to impose tariffs…

Continue Reading Beyond the Price Tag: What Generic Drug Tariffs Could Mean for Patients’ Access to Medication

Huyabio’s HBI-8000 and Opdivo Combination Shows Significant Benefit in Phase 3 Melanoma Study

As reported on Fierce Pharma, Huyabio has reported encouraging Phase 3 results for its investigational oral HDAC inhibitor, HBI-8000, when used alongside Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) in patients…

Continue Reading Huyabio’s HBI-8000 and Opdivo Combination Shows Significant Benefit in Phase 3 Melanoma Study